Developer docs
API playgroundTry for free, no card

Search company profiles

Cerenovus

Full company profile

uuid000a2rt

Namestring
Cerenovus
Legal namestring
CERENOVUS Inc.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Cerenovus is a United States-based neurointerventional medical device manufacturer operating as a wholly-owned subsidiary of Johnson & Johnson MedTech, the medical technology division of Johnson & Johnson (NYSE: JNJ). Headquartered in Irvine, California, the company focuses on devices for acute ischemic stroke intervention and intracranial aneurysm embolization, sold to hospitals and specialized stroke treatment centers through J&J MedTech's enterprise field-sales and hospital procurement channels. Pricing is quote-based and not publicly disclosed, consistent with hospital medical device contracting.

The product portfolio comprises two families. The CereGlide aspiration catheter family, launched in the U.S. in February 2026, consists of the CereGlide 42 and CereGlide 57 aspiration catheters plus the InnerGlide 7 delivery aid; devices feature proprietary variable-stiffness construction, hydrophilic coatings to reduce friction during navigation, and TruCourse technology intended to improve trackability to distal clots in ischemic stroke procedures. The Cerepak detachable coil family (Uniform, Heliform, and Freeform variants) targets intracranial aneurysm embolization and is currently subject to a voluntary Class I recall following higher-than-expected failure-to-detach rates linked to one death and four serious injuries, with no estimated market availability date provided by the company.

The business model is hardware sales to acute care hospitals and neurointerventional centers under procurement contracts, leveraging J&J MedTech's global commercial organization across North America, EMEA, Asia Pacific, and Latin America. The company employs 501-1,000 people, holds four registered trademarks (CereGlide, Cerepak, InnerGlide, TruCourse), and relies on physician education, peer networks, and industry conferences as mid-funnel marketing channels under the J&J MedTech umbrella.

Short descriptiontext

Cerenovus, a wholly-owned subsidiary of Johnson & Johnson MedTech, manufactures neurointerventional medical devices, including the CereGlide aspiration catheter family and the Cerepak detachable coil systems, for use by hospitals and stroke treatment centers in acute ischemic stroke and intracranial aneurysm procedures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neurointerventional devices, aspiration catheters, stroke treatment devices, intracranial aneurysm coils, neurovascular medical devices
Industry3 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKAIAG
Stroke & Vascular Neurology
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurointerventional Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Aspiration Catheter Sales
TypeHardware Sales
Description

Sale of CereGlide aspiration catheters (CereGlide 42, CereGlide 57) and InnerGlide 7 delivery aid for stroke treatment procedures in hospitals and neurointerventional centers

massdevice.com
2Detachable Coil Systems
TypeHardware Sales
Description

Sale of Cerepak detachable coil systems (Uniform, Heliform, Freeform) for intracranial aneurysm embolization. Currently subject to Class I recall with no estimated availability date.

fiercebiotech.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cerenovus manufactures neurointerventional medical devices for the treatment of acute ischemic stroke and intracranial aneurysms. Its product portfolio centers on aspiration catheters (CereGlide 42 and CereGlide 57) with a delivery aid (InnerGlide 7) for clot removal, and detachable coil systems (Cerepak Uniform, Heliform, and Freeform) for aneurysm embolization. Devices are sold to hospitals and specialized stroke centers through J&J MedTech's commercial organization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • CereGlide catheters feature proprietary variable-stiffness construction, hydrophilic coating, and TruCourse technology for trackability
Product overview1 text field

Cerenovus, a unit of Johnson & Johnson MedTech, manufactures neurointerventional medical devices for stroke treatment and intracranial aneurysm procedures. The product portfolio consists of two main device families: the CereGlide aspiration catheter family (CereGlide 42, CereGlide 57, and InnerGlide 7 delivery aid) designed for aspiration-first stroke intervention, and the Cerepak detachable coil systems (Uniform, Heliform, and Freeform variants) designed for embolization of intracranial aneurysms. The CereGlide devices feature proprietary variable-stiffness construction, hydrophilic coating, and TruCourse technology for enhanced trackability and clot removal in ischemic stroke cases.

Product and service6 records
1CereGlide 42 Aspiration Catheter
CategoryMedical Device
Description

Aspiration catheter for neurointerventional procedures designed to reach and remove clots in ischemic stroke cases; features proprietary variable-stiffness construction, hydrophilic coating for reduced friction, and TruCourse technology for enhanced trackability.

2CereGlide 57 Aspiration Catheter
CategoryMedical Device
Description

Aspiration catheter for neurointerventional procedures designed to reach and remove distal clots in ischemic stroke cases; features proprietary variable-stiffness construction, hydrophilic coating for reduced friction, and TruCourse technology for enhanced trackability.

3InnerGlide 7 Delivery Aid
CategoryMedical Device
Description

Delivery aid designed to simplify procedural decisions and enhance performance across device sizes within J&J MedTech's aspiration-first stroke portfolio during neurointerventional workflows.

4Cerepak Uniform Detachable Coil System
CategoryMedical Device
Description

Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall following reports of death and serious injuries linked to higher-than-expected failure to detach rates that can cause hemorrhagic and ischemic strokes.

5Cerepak Heliform Detachable Coil System
CategoryMedical Device
Description

Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall due to higher-than-expected failure to detach rates.

6Cerepak Freeform Detachable Coil System
CategoryMedical Device
Description

Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall due to higher-than-expected failure to detach rates.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Cerenovus is a subsidiary and integral part of Johnson & Johnson MedTech. J&J MedTech announced the launch of CereGlide aspiration catheters in the U.S. market, completing the CereGlide family for its aspiration-first stroke portfolio. The devices were developed within J&J MedTech's neurointerventional business unit to simplify procedural decisions and enhance performance across device sizes in neurointerventional workflows.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeEmerging player
Description

Rapid Medical develops innovative neurovascular devices including the Tigertriever stent retriever and adjustable aneurysm devices, representing an emerging competitor in the same stroke intervention and aneurysm treatment markets as Cerenovus.

TypeDirect peer
Description

MicroPort's neurovascular business offers aspiration catheters and flow diverter devices for stroke and aneurysm treatment, competing directly with Cerenovus in the neurointerventional device market.

TypeEmerging player
Description

Phenox is a European-based neurovascular company specializing in flow diverters and stent retrievers for aneurysm and stroke treatment, representing a focused emerging competitor in Cerenovus's core markets.

TypeBroad incumbent
Description

Terumo's neurovascular division offers access catheters and guidewires used in stroke intervention, providing complementary and competing products to Cerenovus's aspiration catheter and delivery aid portfolio.

TypeBroad incumbent
Description

Integra LifeSciences has a broader neurosurgery and neurocritical care portfolio with adjacent neurovascular offerings, competing in the same hospital and neurosurgeon call point as Cerenovus.

TypeDirect peer
Description

Penumbra is a direct competitor in the neurovascular space, with a leading aspiration thrombectomy platform (Penumbra System, RED reperfusion catheters) that competes head-to-head with Cerenovus's CereGlide family in acute ischemic stroke.

TypeDirect peer
Description

Stryker's Neurovascular division offers stent retrievers (Trevo), aspiration catheters, and detachable coils for aneurysm embolization, directly overlapping with both Cerenovus's CereGlide aspiration line and the recalled Cerepak coil portfolio.

TypeDirect peer
Description

Medtronic's Neurovascular business competes across both ischemic stroke intervention (stent retrievers, aspiration catheters) and aneurysm embolization (detachable coils), making it a broad-based competitor to Cerenovus's neurovascular portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerenovus

Neurointerventional Medical Devicesjnjmedicaldevices.com

Cerenovus, a wholly-owned subsidiary of Johnson & Johnson MedTech, manufactures neurointerventional medical devices, including the CereGlide aspiration catheter family and the Cerepak detachable coil systems, for use by hospitals and stroke treatment centers in acute ischemic stroke and intracranial aneurysm procedures.

What Cerenovus does

Cerenovus is a United States-based neurointerventional medical device manufacturer operating as a wholly-owned subsidiary of Johnson & Johnson MedTech, the medical technology division of Johnson & Johnson (NYSE: JNJ). Headquartered in Irvine, California, the company focuses on devices for acute ischemic stroke intervention and intracranial aneurysm embolization, sold to hospitals and specialized stroke treatment centers through J&J MedTech's enterprise field-sales and hospital procurement channels. Pricing is quote-based and not publicly disclosed, consistent with hospital medical device contracting.

The product portfolio comprises two families. The CereGlide aspiration catheter family, launched in the U.S. in February 2026, consists of the CereGlide 42 and CereGlide 57 aspiration catheters plus the InnerGlide 7 delivery aid; devices feature proprietary variable-stiffness construction, hydrophilic coatings to reduce friction during navigation, and TruCourse technology intended to improve trackability to distal clots in ischemic stroke procedures. The Cerepak detachable coil family (Uniform, Heliform, and Freeform variants) targets intracranial aneurysm embolization and is currently subject to a voluntary Class I recall following higher-than-expected failure-to-detach rates linked to one death and four serious injuries, with no estimated market availability date provided by the company.

The business model is hardware sales to acute care hospitals and neurointerventional centers under procurement contracts, leveraging J&J MedTech's global commercial organization across North America, EMEA, Asia Pacific, and Latin America. The company employs 501-1,000 people, holds four registered trademarks (CereGlide, Cerepak, InnerGlide, TruCourse), and relies on physician education, peer networks, and industry conferences as mid-funnel marketing channels under the J&J MedTech umbrella.

Cerenovus firmographics

Firmographics
Name
Cerenovus
Legal name
CERENOVUS Inc.
Website
https://jnjmedicaldevices.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Cerenovus, a wholly-owned subsidiary of Johnson & Johnson MedTech, manufactures neurointerventional medical devices, including the CereGlide aspiration catheter family and the Cerepak detachable coil systems, for use by hospitals and stroke treatment centers in acute ischemic stroke and intracranial aneurysm procedures.
Ownership category
akta.pro rank

Cerenovus industry classification

Industry
Product category
Neurointerventional Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKAIAG
Stroke & Vascular Neurology
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Neurointerventional devices
  • Aspiration catheters
  • Stroke treatment devices
  • Intracranial aneurysm coils
  • Neurovascular medical devices

Where Cerenovus is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Markets served

Cerenovus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Aspiration Catheter Sales: Sale of CereGlide aspiration catheters (CereGlide 42, CereGlide 57) and InnerGlide 7 delivery aid for stroke treatment procedures in hospitals and neurointerventional centers
  2. Detachable Coil Systems: Sale of Cerepak detachable coil systems (Uniform, Heliform, Freeform) for intracranial aneurysm embolization. Currently subject to Class I recall with no estimated availability date.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Cerenovus product offering

Product offering

Core offering

Cerenovus manufactures neurointerventional medical devices for the treatment of acute ischemic stroke and intracranial aneurysms. Its product portfolio centers on aspiration catheters (CereGlide 42 and CereGlide 57) with a delivery aid (InnerGlide 7) for clot removal, and detachable coil systems (Cerepak Uniform, Heliform, and Freeform) for aneurysm embolization. Devices are sold to hospitals and specialized stroke centers through J&J MedTech's commercial organization.

Product overview

Cerenovus, a unit of Johnson & Johnson MedTech, manufactures neurointerventional medical devices for stroke treatment and intracranial aneurysm procedures. The product portfolio consists of two main device families: the CereGlide aspiration catheter family (CereGlide 42, CereGlide 57, and InnerGlide 7 delivery aid) designed for aspiration-first stroke intervention, and the Cerepak detachable coil systems (Uniform, Heliform, and Freeform variants) designed for embolization of intracranial aneurysms. The CereGlide devices feature proprietary variable-stiffness construction, hydrophilic coating, and TruCourse technology for enhanced trackability and clot removal in ischemic stroke cases.

Differentiator

Problem solved

Functional benefit

Products and services

  • CereGlide 42 Aspiration Catheter Aspiration catheter for neurointerventional procedures designed to reach and remove clots in ischemic stroke cases; features proprietary variable-stiffness construction, hydrophilic coating for reduced friction, and TruCourse technology for enhanced trackability.
  • CereGlide 57 Aspiration Catheter Aspiration catheter for neurointerventional procedures designed to reach and remove distal clots in ischemic stroke cases; features proprietary variable-stiffness construction, hydrophilic coating for reduced friction, and TruCourse technology for enhanced trackability.
  • InnerGlide 7 Delivery Aid Delivery aid designed to simplify procedural decisions and enhance performance across device sizes within J&J MedTech's aspiration-first stroke portfolio during neurointerventional workflows.
  • Cerepak Uniform Detachable Coil System Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall following reports of death and serious injuries linked to higher-than-expected failure to detach rates that can cause hemorrhagic and ischemic strokes.
  • Cerepak Heliform Detachable Coil System Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall due to higher-than-expected failure to detach rates.
  • Cerepak Freeform Detachable Coil System Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall due to higher-than-expected failure to detach rates.

Quantifiable outcome

  • CereGlide catheters feature proprietary variable-stiffness construction, hydrophilic coating, and TruCourse technology for trackability

Companies that use Cerenovus

Customer profile

Segments1 record

Ideal customer profiles1 record

Cerenovus technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cerenovus partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Johnson & Johnson MedTechflagshipStrategic or Co-development Partner · 26 February 2026Cerenovus is a subsidiary and integral part of Johnson & Johnson MedTech. J&J MedTech announced the launch of CereGlide aspiration catheters in the U.S. market, completing the CereGlide family for its aspiration-first stroke portfolio. The devices were developed within J&J MedTech's neurointerventional business unit to simplify procedural decisions and enhance performance across device sizes in neurointerventional workflows.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Cerenovus competitors and assessment

Company assessment

Emerging players

  • Rapid Medical: Rapid Medical develops innovative neurovascular devices including the Tigertriever stent retriever and adjustable aneurysm devices, representing an emerging competitor in the same stroke intervention and aneurysm treatment markets as Cerenovus.
  • Phenox GmbH: Phenox is a European-based neurovascular company specializing in flow diverters and stent retrievers for aneurysm and stroke treatment, representing a focused emerging competitor in Cerenovus's core markets.

Direct peers

  • MicroPort Scientific Corporation: MicroPort's neurovascular business offers aspiration catheters and flow diverter devices for stroke and aneurysm treatment, competing directly with Cerenovus in the neurointerventional device market.
  • Penumbra, Inc. Penumbra is a direct competitor in the neurovascular space, with a leading aspiration thrombectomy platform (Penumbra System, RED reperfusion catheters) that competes head-to-head with Cerenovus's CereGlide family in acute ischemic stroke.
  • Stryker (Neurovascular): Stryker's Neurovascular division offers stent retrievers (Trevo), aspiration catheters, and detachable coils for aneurysm embolization, directly overlapping with both Cerenovus's CereGlide aspiration line and the recalled Cerepak coil portfolio.
  • Medtronic (Neurovascular): Medtronic's Neurovascular business competes across both ischemic stroke intervention (stent retrievers, aspiration catheters) and aneurysm embolization (detachable coils), making it a broad-based competitor to Cerenovus's neurovascular portfolio.

Broad incumbents

  • Terumo (Neurovascular): Terumo's neurovascular division offers access catheters and guidewires used in stroke intervention, providing complementary and competing products to Cerenovus's aspiration catheter and delivery aid portfolio.
  • Integra LifeSciences: Integra LifeSciences has a broader neurosurgery and neurocritical care portfolio with adjacent neurovascular offerings, competing in the same hospital and neurosurgeon call point as Cerenovus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

Cerenovus social profiles

Digital presence

Cerenovus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerenovus leadership team

Management profile

Number of profiles

Profiles1 record

Cerenovus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerenovus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerenovus

What does Cerenovus do?

Cerenovus manufactures neurointerventional medical devices for the treatment of acute ischemic stroke and intracranial aneurysms. Its product portfolio centers on aspiration catheters (CereGlide 42 and CereGlide 57) with a delivery aid (InnerGlide 7) for clot removal, and detachable coil systems (Cerepak Uniform, Heliform, and Freeform) for aneurysm embolization. Devices are sold to hospitals and specialized stroke centers through J&J MedTech's commercial organization.

Is Cerenovus a public or private company?

Cerenovus is a private company. It is classified as corporate owned and is currently operating.

When was Cerenovus founded?

Cerenovus was founded in 2009. It employs 501 to 1,000 people.

Where is Cerenovus based?

Cerenovus is headquartered in Irvine, United States, in the North America region.

How does Cerenovus make money?

Two revenue lines are on record. Aspiration Catheter Sales are the primary driver. The others are detachable Coil Systems.

Who are Cerenovus's main competitors?

Emerging players on record are Rapid Medical and Phenox GmbH. Direct peers are MicroPort Scientific Corporation, Penumbra, Inc., Stryker (Neurovascular) and Medtronic (Neurovascular). Broad incumbents are Terumo (Neurovascular) and Integra LifeSciences.

Does Cerenovus have an API?

No public API is recorded for Cerenovus.

What industry is Cerenovus in?

Cerenovus's product category is Neurointerventional Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesInterventional Neurology Market Research: Industry Trends and Forecast 2035 – PR TimesA market research report on the interventional neurology market describes minimally invasive procedures, devices and technologies for diagnosing and treating neurological and neurovascular disorders such as stroke, aneurysms and arteriovenous malformations. It segments the market by product, application, end user and region, naming Stryker, Medtronic, Penumbra, Johnson & Johnson, MicroPort, Terumo, MicroVention, CERENOVUS, Balt USA and Wallaby Medical as key players.FierceBiotechFDA slaps highest-risk recall notice on J&J Medtech Cerepak detachable coilsThe FDA has classified J&J Medtech's voluntary recall of its Cerepak detachable coil systems as Class I—the highest risk designation—following one death and four serious injuries linked to higher-than-expected failure to detach rates that can cause hemorrhagic and ischemic strokes. The recall, initiated in October by J&J Medtech and its subsidiary Cerenovus, affects multiple versions of the Cerepak Uniform, Heliform and Freeform detachable coil systems designed for embolization of intracranial aneurysms. There is currently no estimated date for when the devices will be available, and J&J Medtech is working to identify alternatives for customers.U.S. Food and Drug AdministrationDetachable Coil System Recall: J&J MedTech/CERENOVUS Inc. Remove CEREPAK Detachable Coil SystemJ&J MedTech and CERENOVUS Inc. issued a recall for certain CEREPAK detachable coil systems due to a higher-than-expected failure rate that could lead to serious injuries or death. The recall involves removing affected products from use and return procedures, with no estimated market availability date provided.BenzingaJohnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates - JohnsoJohnson & Johnson is reportedly exploring the sale of its stroke care unit Cerenovus, engaging advisers to gauge interest from private equity firms and strategic buyers, with the business potentially valued at $1 billion to $1.5 billion. The move aligns with J&J's ongoing efforts to streamline its medical technology division following a series of large acquisitions totaling over $30 billion in the past three years, including Abiomed ($16.6B), Shockwave Medical ($13.1B), and V-Wave ($600M). Jefferies analysts note that Johnson & Johnson maintains strong cash and debt capacity for future deals despite the potential divestment.PR NewswireGlobal Neuroendovascular Coil Market Surpasses $972 Million in 2022, Expected to Reach $1,154 Million by 2028ResearchAndMarkets.com published a market report indicating the global neuroendovascular coil market reached $972 million in 2022 and is projected to grow to $1,154 million by 2028, reflecting a compound annual growth rate of 2.8%. The report highlights technological advancements in coil shapes, lengths, and bioactivity, as well as the growing combination of intracranial stents with coil technology to treat aneurysms and reduce recurrence risk. Industry players are continuing to invest in advanced products, including the Galaxy G3 Mini embolic coil introduced by Cerenovus, a division of Johnson & Johnson.FrontiersRapid ventricular overdrive pacing and other advanced flow-control techniques for the endovascular embolization of vein of galen malformationsThis medical review article details advanced flow-control techniques, such as rapid ventricular overdrive pacing and balloon-assisted embolization, used to improve the safety and efficacy of endovascular treatment for vein of Galen malformations. The text highlights specific medical devices and materials, including Onyx embolic agent by Medtronic and Trufill glue by Cerenovus, which are central to these procedures. It emphasizes that patient-specific approaches are critical due to the technical challenges posed by high-flow arteriovenous shunts.RebrandlyCerenovus hailed as Irish Medtech Company of the Year 2022Cerenovus, a Johnson & Johnson medtech business in Galway, won Medtech Company of the Year at the Irish Medtech Awards. The company develops stroke devices, and J&J announced a €50m investment in its Galway site over three years, creating over 30 jobs.BioWorldCerenovus reports real-world benefits with Embotrap clot-removal devicesCerenovus reported primary results from the real-world EXCELLENT Registry showing positive outcomes with its Embotrap revascularization devices for removing stroke-inducing blood clots. Patients enrolled were treated with Embotrap II or III as first-line therapy for ischemic stroke.BioWorldCerenovus launches Emboguard balloon catheter in US and CanadaCerenovus Inc. is launching the Emboguard balloon guide catheter in the U.S. and Canada for stroke treatment. The device removes blood clots by controlling blood flow during mechanical thrombectomy. It is the latest addition to Cerenovus's stroke portfolio.PR NewswireCERENOVUS Launches Largest Global Registry to Study Stroke-Inducing Blood Clots Removed by ThrombectomyJohnson & Johnson Medical Devices Companies' CERENOVUS business launched the EXCELLENT Registry, the single largest global registry to study stroke-inducing blood clots removed during mechanical thrombectomy using the EMBOTRAP II Revascularization Device, enrolling up to 1,000 ischemic stroke patients at up to 50 clinical sites in the United States and Europe. The registry will collect real-world evidence on clot characteristics including size, composition, and density to determine their impact on patient comorbidities, clinical outcomes, and revascularization rates. Additionally, CERENOVUS received CE mark approval in the European Union for its Geometric Clot Extractor (GCE) Revascularization Device, a novel stroke technology designed to retrieve thrombectomy-resistant clots, and is conducting a controlled evaluation study prior to commercial launch.